Filing Details

Accession Number:
0001237899-14-000063
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-08-27 17:02:26
Reporting Period:
2014-08-26
Filing Date:
2014-08-27
Accepted Time:
2014-08-27 17:02:26
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
872589 Regeneron Pharmaceuticals Inc REGN Pharmaceutical Preparations (2834) 133444607
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1437435 Marc Tessier-Lavigne 777 Old Saw Mill River Road
Tarrytown NY 10591
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-08-26 1,387 $50.91 1,387 No 4 M Direct
Common Stock Disposition 2014-08-26 200 $351.62 1,187 No 4 F Direct
Common Stock Acquisiton 2014-08-27 3,000 $50.91 4,187 No 4 M Direct
Common Stock Disposition 2014-08-27 3,000 $352.20 1,187 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 F Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2014-08-26 1,387 $0.00 1,387 $50.91
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2014-08-27 3,000 $0.00 3,000 $50.91
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
15,279 2021-11-18 No 4 M Direct
12,279 2021-11-18 No 4 M Direct
Footnotes
  1. Represents volume-weighted average price of sales of 3,000 shares of Company stock on August 27, 2014 at prices ranging from $352.15 to $352.34. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 27, 2014 at each separate price.
  2. The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.